Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are the most frequently occurring types of primary liver cancer and together are among the most common incident cancers worldwide. There are a number of modifiable and nonmodifiable HCC and ICC risk factors that have been reported. A review of the existing literature the epidemiology and risk factors for HCC and ICC was performed. There are a number of major infectious, lifestyle, metabolic, and heritable risk factors for both HCC and ICC. Some of these risk factors are either potentially preventable (eg, alcohol and tobacco use) or are currently treatable (eg hepatitis infection). In most cases, the molecular pathway or mechanism by which these etiologic factors cause primary liver cancer has not been well delineated. However, in nearly all cases, it is believed that a given risk factor causes liver injury and inflammation which results in chronic liver disease. Given the rising prevalence of several common HCC and ICC risk factors in the western world, the best opportunities for improving the care of these patients are either through the prevention of modifiable risk factors that are associated with the development of chronic liver disease or the identification of at risk patients, ensuring they are appropriately screened for the development of primary liver cancer, and initiating treatment early.

[1]  K. Okajima,et al.  Congenital bile duct cysts: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. , 1977, American journal of surgery.

[2]  田畑 正久 Bacteria and gallstones etiological significance , 1981 .

[3]  D. Rattner,et al.  Abnormalities of the pancreatic and biliary ducts in adult patients with choledochal cysts. , 1983, Archives of surgery.

[4]  H. Takehara,et al.  Nationwide survey of cases of choledochal cyst. Analysis of coexistent anomalies, complications and surgical treatment in 645 cases. , 1984, Surgical gastroenterology.

[5]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[6]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[7]  P. Johnson,et al.  Etiologic and clinical characteristics of peripheral and hilar cholangiocarcinoma , 1991, Cancer.

[8]  H. Akkız,et al.  by Harwood Academic Publishers Printed in India Endoscopic Retrograde Cholangiopancreatography in the Diagnosis and Management of Choledochal Cysts , 1996 .

[9]  P. Bedossa,et al.  Natural history of liver fibrosis progression in patients with chronic hepatitis C , 1997, The Lancet.

[10]  P Boffetta,et al.  A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.

[11]  Y. Atomi,et al.  Pancreatic disorders associated with anomalous pancreaticobiliary junction. , 1999, Surgery.

[12]  A. Toki,et al.  Bile duct cancer developed after cyst excision for choledochal cyst. , 1999, Journal of hepato-biliary-pancreatic surgery.

[13]  H. Adami,et al.  Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. , 1999, American journal of epidemiology.

[14]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[15]  J. Kaldor,et al.  Estimating progression to cirrhosis in chronic hepatitis C virus infection , 2001, Hepatology.

[16]  S. Porru,et al.  Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. , 2002, American journal of epidemiology.

[17]  R. Hultcrantz,et al.  Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. , 2003, Gastroenterology.

[18]  K. McGlynn,et al.  The Continuing Increase in the Incidence of Hepatocellular Carcinoma in the United States: An Update , 2003, Annals of Internal Medicine.

[19]  B. Grant,et al.  Prevalence and Co-Occurrence of Substance Use Disorders and Independent Mood and Anxiety Disorders , 2004, Archives of general psychiatry.

[20]  K. McGlynn,et al.  Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? , 2004, Journal of hepatology.

[21]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[22]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[23]  B. Bacon,et al.  Relation of hemochromatosis with hepatocellular carcinoma: epidemiology, natural history, pathophysiology, screening, treatment, and prevention. , 2005, The Medical clinics of North America.

[24]  S. Bird,et al.  Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  D. Levy,et al.  Recent trends in smoking and the role of public policies: results from the SimSmoke tobacco control policy simulation model. , 2005, Addiction.

[26]  Shiyuan Liu,et al.  A meta-analysis of case–control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China , 2005, British Journal of Cancer.

[27]  F. Nakayama,et al.  Bacteria and gallstones , 1981, Digestive Diseases and Sciences.

[28]  D. Parkin,et al.  The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.

[29]  H. El‐Serag,et al.  The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[30]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[31]  K. Lindor Characteristics of primary sclerosing cholangitis in the USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[32]  Claude Bouchard,et al.  Effects of bariatric surgery on mortality in Swedish obese subjects. , 2007, The New England journal of medicine.

[33]  J. Olsen,et al.  Risk factors for intrahepatic cholangiocarcinoma in a low‐risk population: A nationwide case‐control study , 2007, International journal of cancer.

[34]  B. Graubard,et al.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  S. Larsson,et al.  Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies , 2007, British Journal of Cancer.

[36]  D. Dempsey,et al.  Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects , 2008 .

[37]  A. Tavill,et al.  Liver Disease in Alpha 1-Antitrypsin Deficiency: A Review , 2008, The American Journal of Gastroenterology.

[38]  Manal M. Hassan,et al.  Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case‐control study , 2008, International journal of cancer.

[39]  K. Straif,et al.  Meta-analysis of epidemiologic studies on cigarette smoking and liver cancer. , 2009, International journal of epidemiology.

[40]  C. H. Lee,et al.  Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma , 2009, British Journal of Cancer.

[41]  H. El‐Serag,et al.  Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population‐based study of U.S. veterans , 2009, Hepatology.

[42]  M. Mondelli,et al.  Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. , 2009, Journal of hepatology.

[43]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[44]  G. Zanette,et al.  Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[45]  Lequn Li,et al.  Evaluation of Risk Factors and Clinicopathologic Features for Intrahepatic Cholangiocarcinoma in Southern China: A Possible Role of Hepatitis B Virus , 2011, Annals of Surgical Oncology.

[46]  Y. Kuo,et al.  Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  D. Harnois,et al.  Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression , 2010 .

[48]  Manal M. Hassan,et al.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma , 2010, Cancer.

[49]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[50]  T. Therneau,et al.  Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[51]  William M. Lee,et al.  Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. , 2011, Gastroenterology.

[52]  S. Altekruse,et al.  Histological classification of liver and intrahepatic bile duct cancers in SEER registries. , 2011, Journal of registry management.

[53]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[54]  B. Graubard,et al.  Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database , 2011, Hepatology.

[55]  N. Chalasani,et al.  Nonalcoholic fatty liver disease (NAFLD): Is it really a serious condition? , 2012, Hepatology.

[56]  H. El‐Serag,et al.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[57]  H. El‐Serag,et al.  458 The Rising Incidence of Hepatocellular Carcinoma in the United States: an Update , 2012 .

[58]  J. Shieh,et al.  Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies , 2012, Gut.

[59]  W. Palmer,et al.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.

[60]  Jasmin A. Tiro,et al.  Failure Rates in the Hepatocellular Carcinoma Surveillance Process , 2012, Cancer Prevention Research.

[61]  Katherine M Flegal,et al.  Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. , 2012, JAMA.

[62]  S. Lemon,et al.  Is hepatitis C virus carcinogenic? , 2012, Gastroenterology.

[63]  H. El‐Serag,et al.  Epidemiology of viral hepatitis and hepatocellular carcinoma. , 2012, Gastroenterology.

[64]  Paolo Chiodini,et al.  Metabolic Syndrome and Risk of Cancer , 2012, Diabetes Care.

[65]  M. Murad,et al.  Anti-Diabetic Medications and the Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[66]  N. Yang,et al.  Characteristics of intrahepatic cholangiocarcinoma in patients with hepatitis B virus infection: clinicopathologic study of resected tumours , 2013, Journal of viral hepatitis.

[67]  Masahira Hattori,et al.  Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome , 2013, Nature.

[68]  C. Cho,et al.  Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy , 2013, British Journal of Cancer.

[69]  B. Graubard,et al.  Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States , 2013, The American Journal of Gastroenterology.

[70]  Sahil Mittal,et al.  Epidemiology of hepatocellular carcinoma: consider the population. , 2013, Journal of clinical gastroenterology.

[71]  T. Therneau,et al.  Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk , 2013, Hepatology.

[72]  U. Nöthlings,et al.  Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort , 2013, International journal of cancer.

[73]  C. Pairojkul,et al.  Roles of liver fluke infection as risk factor for cholangiocarcinoma , 2014, Journal of hepato-biliary-pancreatic sciences.

[74]  H. El‐Serag,et al.  Secular Trends in the Incidence of Cholangiocarcinoma in the USA and the Impact of Misclassification , 2014, Digestive Diseases and Sciences.

[75]  Carlo La Vecchia,et al.  Hepatocellular carcinoma epidemiology. , 2014, Best practice & research. Clinical gastroenterology.

[76]  M. Thiele,et al.  Large Variations in Risk of Hepatocellular Carcinoma and Mortality in Treatment Naïve Hepatitis B Patients: Systematic Review with Meta-Analyses , 2014, PloS one.

[77]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[78]  M. Karin,et al.  ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. , 2014, Cancer cell.

[79]  L. Kaplan,et al.  Obesity and liver disease: the epidemic of the twenty-first century. , 2014, Clinics in liver disease.

[80]  H. El‐Serag,et al.  HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV , 2014, Hepatology.

[81]  J. Buring,et al.  Coffee Consumption and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[82]  J. Ioannidis,et al.  Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies , 2015, BMJ : British Medical Journal.

[83]  F. Sung,et al.  Combination Therapy of Metformin and Statin May Decrease Hepatocellular Carcinoma Among Diabetic Patients in Asia , 2015, Medicine.

[84]  B. Wang,et al.  Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[85]  L. Hou,et al.  NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project , 2015, Cancer Prevention Research.

[86]  L. Henry,et al.  Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009 , 2015, Hepatology.

[87]  Hao Li,et al.  Hepatitis C virus infection and the risk of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis of 16 case-control studies , 2015, World Journal of Surgical Oncology.

[88]  A. Bondi,et al.  Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review. , 2015, World journal of gastroenterology.

[89]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[90]  L. Roberts,et al.  Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. , 2016, Chinese clinical oncology.

[91]  B. Graubard,et al.  Population attributable fractions of risk factors for hepatocellular carcinoma in the United States , 2016, Cancer.

[92]  M. Braddock,et al.  Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma , 2016, Scientific Reports.

[93]  S. Kottilil,et al.  Hepatitis C genotype 3 disease , 2016, Hepatology International.

[94]  R. Wong,et al.  Sex‐specific and race/ethnicity‐specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000–2011 Surveillance, Epidemiology and End Results registry , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[95]  K. Flegal,et al.  Trends in Obesity Among Adults in the United States, 2005 to 2014. , 2016, JAMA.

[96]  Peter J. Richardson,et al.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection , 2016, Hepatology.

[97]  P. Rosenberg,et al.  Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  H. El‐Serag,et al.  Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[99]  E. Kang,et al.  Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case‐control study , 2017, International journal of cancer.

[100]  C. la Vecchia,et al.  Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies , 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[101]  H. El‐Serag,et al.  Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. , 2017, Gastroenterology.

[102]  V. Cogliano International Agency for Research on Cancer (IARC) , 2018, The Grants Register 2019.